Second opinions from firsthand experience.

Healthcasts is the only clinical platform where you can consult real peers, search verified case data, and access AI consensus, all at the point of care. Free for licensed clinicians.

Create free account

Collaborate

Post patient scenarios and receive peer feedback from your network of verified, practicing clinicians.

Contribute

Share your clinical experience and build a reputation in your specialty while helping colleagues improve care.

Search

Explore our database of consultations by medication, indication, and treatment.

Learn

Our AI consensus engine distills key peer insights into clear, actionable intelligence you can act on immediately.

Platform capabilities

Fits naturally into your workflow

Clinicians use Healthcasts to post questions on complex cases, scan active discussions to see how peers are approaching similar decisions, contribute their own judgment to help colleagues, and surface fast answers through search or Consensus Summaries when time is short.

Search

Find insights when time matters

Search real, peer-provided experiences to improve care. When you're at the bedside and need a fast answer grounded in clinical reality, not a generic summary.

Search insights
Case search
GLP-1 agonist CKD stage 3 type 2 diabetes 2,847 results
ENDOCRINOLOGY
GLP-1 use in CKD 3b: Real-world dosing patterns and outcomes across 214 cases
214 peer cases · 89% consensus · Updated 2 days ago
NEPHROLOGY
Renal outcomes with semaglutide in T2DM patients: eGFR trend analysis
147 peer cases · 76% consensus · Updated 1 week ago
INTERNAL MEDICINE
Second-line agent selection in T2DM with comorbid CKD: practitioner survey
398 peer cases · 82% consensus · Updated 3 days ago
Case Discussion

Post & get provider feedback

Describe your case in full: symptoms, differentials, uncertainties. Get real responses from verified physicians who've navigated similar clinical complexity.

Post a case
Active consultation
CARDIOLOGY
AK
Dr. A. Kim
Internal Medicine
"68yo F with known HFrEF, now presenting with NYHA Class III symptoms despite optimal medical therapy. Considering ICD referral. What's your threshold?"
MR
PL
JS
+9
135 peer responses · 4 min ago
MR
Dr. M. Rivera
Cardiology · Verified
"At Class III with EF <35%, AHA/ACC guidelines are clear: class I indication for ICD if life expectancy >1yr. I'd also ensure she's on max tolerated dose of everything first."
Consensus

See where peers agree, fast

Healthcasts' Consensus Summaries provide the general agreement from contributors, so you can act without reading hundreds of individual comments. Decisive, not diluted.

See a Consensus
AI Consensus Engine
Clinical Consensus
SGLT2 inhibitors in CKD 3b + T2DM · 312 responses
Strong peer consensus supports SGLT2 inhibitor use in CKD 3b (eGFR 30–44) for T2DM patients, citing reno- and cardioprotective benefits that outweigh modest GFR reduction risk. Most respondents recommend starting at lowest dose with monthly eGFR monitoring.
Consensus strength 84%
Based on 312 peer responses from Nephrology, Endocrinology, and Internal Medicine. Updated 6 hours ago.
Specialty breakdown
Nephrology
Endocrinology
Internal Med
Collaboration

Cross-specialty perspectives in one place

Cardiology, oncology, dermatology, GI: side by side, not in silos. When a case crosses specialties, you need perspectives from all directions.

Collaborate with peers
Cross-specialty view
Amyloidosis workup · 3 specialties weighing in
CARDIOLOGY
"Echo findings with septal thickening and sparkling pattern. Strongly recommend cardiac MRI and fat pad biopsy before EP referral."
Dr. P. Lee · 2 min ago
HEMATOLOGY
"If AL amyloid: serum free light chains and SPEP first. Don't delay heme workup waiting on biopsy."
Dr. S. Park · 5 min ago
NEPHROLOGY
"Creatinine trend matters. If rising, consider renal biopsy concurrently. It can confirm systemic involvement."
Dr. J. Okonkwo · 9 min ago
Contribute

Your suggestion could be a peer's breakthrough

Every comment you share helps others make smarter clinical decisions and extends your impact on patient care far beyond your own practice.

Make a comment
Your contribution
ONCOLOGY · CASE #4821
"NSCLC patient on pembrolizumab, now with grade 2 pneumonitis. Continue, hold, or discontinue?"
14 responses · 2 min ago
You
Your response
Oncology · Verified
"Hold pembrolizumab for grade 2. Start pred 1mg/kg/day. Rechallenge at grade 0–1 after taper. Most grade 2 can safely rechallenge per our experience."
AK
JT
+12
Watching this case
Your insight matters

How it works

From questions to answers

Three steps from clinical uncertainty to peer-backed confidence.

1

Create your free, NPI-verified account

Verification takes minutes. Your credentials confirm you're a licensed provider, ensuring every response you receive comes from a peer, not an algorithm.

2

Search, post, or browse

Find existing peer discussions, post your specific case for real-time feedback, or browse Consensus Summaries for fast distilled perspectives across hundreds of cases.

3

Act with peer-backed confidence

Close the gap between the guideline and your clinical reality. Then contribute your own insight. Every comment extends your impact beyond your own practice.

Your next clinical decision
deserves peer input.

Join thousands of verified healthcare practitioners on the platform designed for the reality of medicine.

Sign up for free